Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Schwab

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2017
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-convertersNicholas Schwab, Tilman Schneider-Hohendorf, Tammy Hoyt, et al.
Annals of Neurology|January 23, 2026
Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine TreatmentTilman Schneider-Hohendorf, Maria Eveslage, Timo Wirth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2016
Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsetsCatharina C Gross, Andreas Schulte-Mecklenbeck, Uta Hanning, et al.
Plos One|November 19, 2010
Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosisSebastian Doerck, Kerstin Göbel, Gesa Weise, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2018
Sex bias in MHC I-associated shaping of the adaptive immune systemTilman Schneider-Hohendorf, Dennis Görlich, Paula Savola, et al.
Annals of Clinical and Translational Neurology|September 24, 2025
Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell CompositionRegina Berkovich, Tilman Schneider-Hohendorf, Eric Baetscher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2017
Dual action by fumaric acid esters synergistically reduces adhesion to human endotheliumJohanna Breuer, Sebastian Herich, Tilman Schneider-Hohendorf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2020
High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patientsTilman Schneider-Hohendorf, Andreas Schulte-Mecklenbeck, Patrick Ostkamp, et al.
The Journal of Experimental Medicine|August 20, 2014
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cellsTilman Schneider-Hohendorf, Jan Rossaint, Hema Mohan, et al.
Iscience|July 29, 2025
B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumabTilman Schneider-Hohendorf, Christian Wünsch, Andreas Schulte-Mecklenbeck, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2017
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-convertersNicholas Schwab, Tilman Schneider-Hohendorf, Tammy Hoyt, et al.
Annals of Neurology|January 23, 2026
Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine TreatmentTilman Schneider-Hohendorf, Maria Eveslage, Timo Wirth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2016
Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsetsCatharina C Gross, Andreas Schulte-Mecklenbeck, Uta Hanning, et al.
Plos One|November 19, 2010
Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosisSebastian Doerck, Kerstin Göbel, Gesa Weise, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2018
Sex bias in MHC I-associated shaping of the adaptive immune systemTilman Schneider-Hohendorf, Dennis Görlich, Paula Savola, et al.
Annals of Clinical and Translational Neurology|September 24, 2025
Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell CompositionRegina Berkovich, Tilman Schneider-Hohendorf, Eric Baetscher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2017
Dual action by fumaric acid esters synergistically reduces adhesion to human endotheliumJohanna Breuer, Sebastian Herich, Tilman Schneider-Hohendorf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2020
High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patientsTilman Schneider-Hohendorf, Andreas Schulte-Mecklenbeck, Patrick Ostkamp, et al.
The Journal of Experimental Medicine|August 20, 2014
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cellsTilman Schneider-Hohendorf, Jan Rossaint, Hema Mohan, et al.
Iscience|July 29, 2025
B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumabTilman Schneider-Hohendorf, Christian Wünsch, Andreas Schulte-Mecklenbeck, et al.
Pageof 8